arrow
A

Akihiko Shimomura

National Centre for Global Health and Medicine
H指数:28
被引数:3,711

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)

转移性乳腺癌患者关注的生活质量问题:欧洲癌症研究与治疗组织转移性乳腺癌模块(EORTC QLQ-MBR)的第一阶段和第二阶段开发

Breast
IF7.9
2026-09-050
OA
International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

国际IV期实地研究以验证欧洲癌症研究与治疗组织问卷用于评估癌症幸存者的健康相关生活质量:EORTC QLQ-SURV100

2026-08-010
PRE
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer

POLH和RAD51基因的种系变异是激素受体阴性年轻发病乳腺癌风险的候选变异。

2025-11-280
OAAI
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma

与早发性肺腺癌风险相关的致病性和中等外显率生殖细胞系变异的基因组特征

2025-06-150
OAAI
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) (Aug, 10.1007/s12282-024-01614-1, 2024)
2024-09-200
OAAI
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

曲妥珠单抗deruxtecan治疗脑和/或软脑膜转移的HER2-positive乳腺癌患者: 使用多中心回顾性研究 (roset-bm) 数据进行的更新的总生存分析

2024-08-125
OAAI
Effectiveness and prognostic predictors of primary systemic therapy for de-novo Stage IV breast cancer - Supplementary analysis of JCOG1017 PRIM-BC
2024-05-020
PRE